Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Keros Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 139 | 155 | +16 |
| Shares | 35.9M | 35.3M | −649.3K (−1.8%) |
| Value | $479.6M | $558.0M | +$78.5M (+16.4%) |
New holders (29)
Institutions that held Keros Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (13)
Institutions that held Keros Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Janus Henderson Group PLC | 472,392 | $6.31M |
| Newtyn Management, LLC | 246,857 | $3.30M |
| Verition Fund Management LLC | 171,763 | $2.29M |
| Simplex Trading, LLC | 90,735 | $1.21M |
| Nebula Research & Development LLC | 90,406 | $1.21M |
| XTX Topco Ltd | 54,145 | $722.8K |
| UBS Oconnor LLC | 37,891 | $505.8K |
| Lazard Asset Management LLC | 21,849 | $291.0K |
| Fox Run Management, L.L.C. | 12,354 | $164.9K |
| Profund Advisors LLC | 11,421 | $152.5K |
| Raymond James Financial Inc | 100 | $1.33K |
| Skopos Labs, Inc. | 91 | $1.22K |
| Geneos Wealth Management Inc. | 83 | $1.11K |